InvestorsHub Logo
Followers 31
Posts 3389
Boards Moderated 0
Alias Born 08/04/2009

Re: None

Monday, 08/10/2020 6:54:10 PM

Monday, August 10, 2020 6:54:10 PM

Post# of 27563
For all those to whom the news was intentionally written "too technical" to be sold as progress (LOL).
"Anti-SARS-CoV-2 spike titers to IBIO-201 were observed 21 days after immunization (A titer is a measure of the amount or concentration of a substance in a solution. It usually refers to the amount of antibodies found in a person's blood). Titers continued to increase over the 42-day study. Distinct, favorable Th1 and Th2 immune profiles were observed (this means vaccine is working and increasing in potency over time)"

Source: https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/83035792/ibio-provides-update-on-ibio-201-covid-19-vaccine

The iBio Collection
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

#iBio $iBio iBio


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IBIO News